Cargando…

The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021

BACKGROUND AND OBJECTIVE: Hong Kong, like many parts of Asia, faces a high burden of hepatocellular carcinoma (HCC) caused by high endemic rates of hepatitis B virus infection. Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical, transarterial, ablative, ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Tan-To, Yu, Simon Chun-Ho, Chan, Stephen L., Poon, Ronnie T. P., Kwok, Philip, Lee, Ann-Shing, Tai, Anna, Tam, Derek, Cheung, Chin-Cheung, Lai, Tak-Wing, Chia, Nam-Hung, Law, Ada, Shum, Tracy, Lam, Yim-Kwan, Lau, Vince, Lee, Victor, Chong, Charing, Tang, Chung-Ngai, Yau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282685/
https://www.ncbi.nlm.nih.gov/pubmed/37351136
http://dx.doi.org/10.21037/hbsn-21-405
_version_ 1785061181352837120
author Cheung, Tan-To
Yu, Simon Chun-Ho
Chan, Stephen L.
Poon, Ronnie T. P.
Kwok, Philip
Lee, Ann-Shing
Tai, Anna
Tam, Derek
Cheung, Chin-Cheung
Lai, Tak-Wing
Chia, Nam-Hung
Law, Ada
Shum, Tracy
Lam, Yim-Kwan
Lau, Vince
Lee, Victor
Chong, Charing
Tang, Chung-Ngai
Yau, Thomas
author_facet Cheung, Tan-To
Yu, Simon Chun-Ho
Chan, Stephen L.
Poon, Ronnie T. P.
Kwok, Philip
Lee, Ann-Shing
Tai, Anna
Tam, Derek
Cheung, Chin-Cheung
Lai, Tak-Wing
Chia, Nam-Hung
Law, Ada
Shum, Tracy
Lam, Yim-Kwan
Lau, Vince
Lee, Victor
Chong, Charing
Tang, Chung-Ngai
Yau, Thomas
author_sort Cheung, Tan-To
collection PubMed
description BACKGROUND AND OBJECTIVE: Hong Kong, like many parts of Asia, faces a high burden of hepatocellular carcinoma (HCC) caused by high endemic rates of hepatitis B virus infection. Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical, transarterial, ablative, radiotherapeutic and systemic modalities. This publication summarizes the latest evidence-based recommendations on how these modalities should be used. METHODS: In two meetings held in 2020, a multidisciplinary panel of surgeons, oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC, with an emphasis on treatment of HCC not amenable to surgical resection. Close attention was paid to new evidence published since the previous version of these statements in 2018. KEY CONTENT AND FINDINGS: The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC. Since the previous version of these statements, considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence. CONCLUSIONS: Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection. In particular, there is a need for more evidence to aid physicians in the selection of second-line systemic therapies, as currently most data are limited to patients with disease progression on first-line sorafenib.
format Online
Article
Text
id pubmed-10282685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-102826852023-06-22 The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021 Cheung, Tan-To Yu, Simon Chun-Ho Chan, Stephen L. Poon, Ronnie T. P. Kwok, Philip Lee, Ann-Shing Tai, Anna Tam, Derek Cheung, Chin-Cheung Lai, Tak-Wing Chia, Nam-Hung Law, Ada Shum, Tracy Lam, Yim-Kwan Lau, Vince Lee, Victor Chong, Charing Tang, Chung-Ngai Yau, Thomas Hepatobiliary Surg Nutr Review Article BACKGROUND AND OBJECTIVE: Hong Kong, like many parts of Asia, faces a high burden of hepatocellular carcinoma (HCC) caused by high endemic rates of hepatitis B virus infection. Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical, transarterial, ablative, radiotherapeutic and systemic modalities. This publication summarizes the latest evidence-based recommendations on how these modalities should be used. METHODS: In two meetings held in 2020, a multidisciplinary panel of surgeons, oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC, with an emphasis on treatment of HCC not amenable to surgical resection. Close attention was paid to new evidence published since the previous version of these statements in 2018. KEY CONTENT AND FINDINGS: The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC. Since the previous version of these statements, considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence. CONCLUSIONS: Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection. In particular, there is a need for more evidence to aid physicians in the selection of second-line systemic therapies, as currently most data are limited to patients with disease progression on first-line sorafenib. AME Publishing Company 2023-05-06 2023-06-01 /pmc/articles/PMC10282685/ /pubmed/37351136 http://dx.doi.org/10.21037/hbsn-21-405 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Cheung, Tan-To
Yu, Simon Chun-Ho
Chan, Stephen L.
Poon, Ronnie T. P.
Kwok, Philip
Lee, Ann-Shing
Tai, Anna
Tam, Derek
Cheung, Chin-Cheung
Lai, Tak-Wing
Chia, Nam-Hung
Law, Ada
Shum, Tracy
Lam, Yim-Kwan
Lau, Vince
Lee, Victor
Chong, Charing
Tang, Chung-Ngai
Yau, Thomas
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
title The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
title_full The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
title_fullStr The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
title_full_unstemmed The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
title_short The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
title_sort hong kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282685/
https://www.ncbi.nlm.nih.gov/pubmed/37351136
http://dx.doi.org/10.21037/hbsn-21-405
work_keys_str_mv AT cheungtanto thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT yusimonchunho thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT chanstephenl thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT poonronnietp thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT kwokphilip thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT leeannshing thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT taianna thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT tamderek thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT cheungchincheung thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT laitakwing thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT chianamhung thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT lawada thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT shumtracy thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT lamyimkwan thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT lauvince thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT leevictor thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT chongcharing thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT tangchungngai thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT yauthomas thehongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT cheungtanto hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT yusimonchunho hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT chanstephenl hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT poonronnietp hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT kwokphilip hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT leeannshing hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT taianna hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT tamderek hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT cheungchincheung hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT laitakwing hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT chianamhung hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT lawada hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT shumtracy hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT lamyimkwan hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT lauvince hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT leevictor hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT chongcharing hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT tangchungngai hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021
AT yauthomas hongkongconsensusstatementsonunresectablehepatocellularcarcinomanarrativereviewandupdatefor2021